-
Trump rejects international regulation of AI
-
French Holocaust denier jailed for eight months
-
How is the EU approaching record fuel prices?
-
Oil prices slide, AI stock buzz fades
-
Sri Lanka's Colombage strikes on debut as England dismissed for 265 in first ODI
-
Trump threatens to 'annihilate' Iran in bombastic UN speech
-
Hurricane Polo strengthens to top category 5 off Mexico
-
Prada's skirts take centre stage as Milan Fashion Week begins
-
11 hurt as teen opens fire outside school in western Turkey
-
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
UN chief says 'Big Oil' treats atmosphere as open sewer
-
Brazil's Flavio Bolsonaro turns scandal into poll gains
-
Tunisia says 2026 summer hottest on record
-
Republican senator seeks probe of Trump Jr Russian-funded wedding
-
England's Rashid out of Sri Lanka ODIs with hand injury
-
Memoir by Diana's brother goes on sale after rocking UK monarchy
-
Houthis accuse Saudi Arabia of deadly strikes as thousands flee
-
Newcomers South Korea face holders Italy in Davis Cup finals
-
Stocks climb as oil slides, AI buzz returns
-
Japan's Kojima sounds Marchand warning with Asian Games gold
-
India cricketers win in style as Afghan savours 'special' Games silver
-
England rugby star Pollock signs new Northampton deal
-
La Liga president hits out at Real Madrid refereeing 'conspiracy' claims
-
STARTRADER Expands Its Chinese Equity CFD Range with CXMT and Unitree Robotics
-
MEXC Launches “Real Stocks, Real Friends” with Rewards for Bringing Friends to Wall Street
-
MEXC Expands Opportunity Compass with Stock Trading Handbook to Help Crypto Users Build Investment Knowledge
-
Mbappe continues media push for Ballon d'Or recognition
-
England paceman Wood retires from international cricket
-
Stocks rise on AI buzz, oil prices cool
-
Magnificent Mandhana's 79 helps India to Asian Games cricket gold
-
India narrowly survive huge scare against minnows Japan
-
Marchand 'stressed' about racing Japanese rivals at LA Olympics
-
Missing F-35 fighter parts 'not sensitive', says Australia minister
-
Mobile boat clinics bring healthcare to India's remote islands
-
Cambodia showcases scams crackdown with global conference
-
Former India paceman Zaheer Khan named Chennai coach in IPL
-
Afghan cyclist who disguised herself as man wins Asian Games silver
-
Six-year-old Chinese girl sets world record with Rubik's Cube
-
Typhoon Dujuan leaves four dead in Japan, 45,000 houses without power
-
Swimming prodigy Yu, 13, says 'interviews way harder than racing'
-
G7 leaders condemn Houthi strikes on Saudi Arabia
-
Star coaches make their bows as Nations League returns
-
Google data centre sparks protests in Austria
-
Rams bounce back as Giants reel from Dart injury
-
Shin Ohashi: Junk food-loving teen and Japan's next big swimming hope
-
In Bangladesh, Pakistan's Jinnah photo stirs anger
-
Stocks rise on AI buzz, drop in oil prices
-
Two New Zealand naval ships transit Taiwan Strait
-
China's robot dancers limber up for America's Got Talent final
-
Zidane gets down to work as France start new era
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
T.Sanchez--AT